Haier Biomedical 2025 Annual Report
Analysis based on 9 articles · First reported Apr 30, 2026 · Last updated Apr 30, 2026
The positive 2025 annual report from Haier Biomedical, highlighting record overseas revenue and significant AI-powered growth, is expected to positively impact its stock price and investor confidence. The company's strategic targets and technological breakthroughs position it for continued expansion in the global life sciences and medical solutions markets.
Haier Biomedical, a global leader in life sciences and medical solutions, published its 2025 annual report, revealing full-year revenue of 2.33 billion yuan (USD 340.77 million) and a record-high overseas revenue of 840 million yuan (USD 122.85 million), accounting for 36% of total revenue. The company achieved double-digit growth across all international business sectors, including 26.0% in Asia-Pacific and 16.0% in Europe. Haier Biomedical unveiled a strategic blueprint for 'growth leapfrogging' through market, industry, and model leaps, aiming to build a world-leading integrated life science tools and intelligent productivity platform. New business segments contributed 48.5% of total revenue, and AI-powered applications accounted for 15% of total revenue, up 2.5 percentage points from 2024. The company's R&D investment reached 320 million yuan, leading to a 50% increase in new invention patents. Haier Biomedical also achieved significant milestones, such as its plasma separation system receiving EU MDR certification and mastering 100,000-rpm ultra-high-speed centrifugation technology. The company outlined three-year '543' strategic targets, focusing on localized development, AI-driven innovation, and mergers and acquisitions to drive future growth.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard